As mentioned previously, it is known that mutations in B2M would impact tumor neoantigen presentation and immune activation (Argyropoulos et al., 2017) B2M-mutated CRCs have been shown to be associated with higher levels of PD-1 positive T cells, pointing toward potential PD-1 inhibitor resistance (as has already been observed in melanoma) (Janikovits et al., 2018). The gene discussed is B2M; the disease is melanoma.